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A B S T R A C T   
Bacteriocins, a class of antimicrobial peptide produced by bacteria, may offer a potential alternative to tradi-
tional antibiotics, an important step towards mitigating the ever-increasing antimicrobial resistance crisis. They 
are active against a range of clinically relevant Gram-positive and Gram-negative bacteria. Bacteriocins have 
been discussed in the literature for over a century. Although they are used as preservatives in food, no medicine 
based on their antimicrobial activity exists on the market today. In order to formulate them into clinical anti-
biotics, pre-formulation studies on their biophysical and physicochemical properties that will influence their 
activity in vivo and their stability during manufacture must be elucidated. Thermal, pH and enzymatic stability of 
bacteriocins are commonly studied and regularly reported in the literature. Solubility, permeability and aggre-
gation properties on the other hand are less frequently reported for many bacteriocins, which may contribute to 
their poor clinical progression. Promising cytotoxicity studies report that bacteriocins exhibit few cytotoxic ef-
fects on a variety of mammalian cell lines, at active concentrations. This review highlights the lack of quanti-
tative data and in many cases even qualitative data, on bacteriocins’ solubility, stability, aggregation, 
permeability and cytotoxicity. The formulation strategies that have been explored to date, proposed routes of 
administration, trends in in vitro/in vivo behaviour and efforts in clinical development are discussed. The future 
promise of bacteriocins as a new generation of antibiotics may require tailored local delivery strategies to fulfil 
their potential as a force to combat antimicrobial-resistant bacterial infections.   
1. Introduction 
Antimicrobial resistance (AMR) is a major contributing factor to 
mortality and morbidity across the world with major public health and 
societal implications [1,2]. While antibiotics have revolutionised med-
icine, AMR poses a major threat to hinder and even reverse this progress. 
AMR occurs due to genetic factors intrinsic to bacteria; cellular level 
resistance with mutations and horizontal gene transfer (HGT) of resis-
tance determinants, and community-level resistance including biofilms 
or persister cells [3]. The rise in AMR has been accelerated by the 
inappropriate use of antibiotics in agriculture, food and pharmaceu-
tical/medical sectors [4]. The World Health Organisation (WHO) has 
attempted to focus research towards novel therapeutics as the number of 
antimicrobial agents in the clinical pipeline is not sufficient to mitigate 
this problem and the rate of development of novel antimicrobials is not 
fast enough. They are also steering research towards systems to effec-
tively monitor the rising levels of AMR [5,6]. One potential new class of 
antibiotics are antimicrobial peptides (AMPs), and in particular, a class 
of AMPs called bacteriocins [7-9]. AMPs are gene-encoded polypeptides 
that are ribosomally produced by nearly all organisms from bacteria to 
plants [10]. They are small (30–60 amino acids), mostly cationic, hy-
drophobic or amphiphilic peptides [11-13]. Certain Gram-negative 
bacteriocins resemble eukaryotic defensins, where ribosomally pro-
duced bacteriocins exhibit narrow activity ranges, and non-ribosomally 
produced bacteriocins demonstrate wider activity ranges to bacteria and 
fungi [14]. There are a variety of databases showcasing documented 
AMPs [15-17]. For example, LAMP2, set up in 2013 by Dr. Wu Hungyu 
[18,19], APD3, set up in 2015 by Dr. Guangshun Wang [20,21], and 
DRAMP, the database established by Heng, Zheng et al., [16,22]. Koo 
et al. reported 34 AMPs in preclinical trials in 2019 and 27 in clinical 
trials. There have been 10 AMPs discontinued during drug development 
due to failure at phase I or II of clinical trials [23]. Despite the high 
number of AMPs in development, only a few AMPs have reached the 
market e.g. daptomycin, gramidicin, bacitracin, caspofungin, 
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dalbavancin, PAC-113 (P-113) and bilracidin. The molecular weight of 
these are all low, < 2 kDa, and the stability of the formulations is limited 
[24-28]. 
A bacteriocin is an AMP produced by bacterial strains [29]. The 
producer bacterium has specific immunity against the bacteriocin it 
produces. Bacteriocins are categorised in terms of their chemical/ 
biochemical composition and whether the producing bacterium is Gram- 
positive or Gram-negative. Gram-positive bacteriocins are divided into 
three major classes, by Rea et al.: Class Ia, Ib and Ic – the lantibiotics, the 
labrinthopeptins and the sactibiotics respectively; Class II – unmodified, 
heat stable, positively charged bacteriocins which can be subdivided 
further into four different classes; class IIa- pediocin-like bacteriocins, 
class IIb- two-peptide unmodified bacteriocins, class IIc- circular bac-
teriocins and class IId - unmodified, linear, non-pediocin-like, single 
peptide bacteriocins (other) and Class III - bacteriolysins [30]. Rebuffat 
et al. best describe Gram-negative bacteriocins which are segregated into 
three categories, colicins, microcins and phage tail-like bacteriocins 
[31]. 
Several bacteriocins have been identified with activity against clin-
ically relevant Gram-negative and Gram-positive bacteria. These include 
bacterial strains that show resistance to commonly used antibiotics, such 
as C. difficile, methicillin-resistant S. aureus (MRSA), S. pneumonia and 
vancomycin-resistant enterococci (VRE) [9,32-34]. Thus, bacteriocins 
may be a potential alternative to traditional antibiotics. There are a 
variety of different modes of action employed by bacteriocins to inhibit 
competing bacteria. Briefly, this can involve the binding of bacteriocins 
to the pyrophosphate moiety of lipid II at the cell wall of Gram-positive 
cells, ultimately leading to the disruption of cell wall biosynthesis 
(Fig. 1a). Other modes for Gram-positive bacteriocins involve pore 
formation with subsequent leakage of intracellular components (Fig. 1b 
and c). Gram-negative bacteriocins typically utilise translocation across 
the cell membrane (Fig. 1d). The different modes of action employed by 
bacteriocins are best described in a recent review by Meade, et al. [14]. 
Dicks et al. provides an overview of bacteriocins’ potential in medical 
applications, assessing their capability as spermicides/contraceptives 
and for treating upper respiratory tract infections, urogenital tract in-
fections and systemic infections. They also address issues such as 
resistance and immunity [35]. Some 230 identified bacteriocins with a 
wide range of antimicrobial effects and properties are documented in 
Bactibase, a free-to-access online database set up by Dr. Hammani [36]. 
As bacteriocins exhibit antimicrobial activity against clinically relevant 
pathogens that have become resistant to current antimicrobial thera-
peutics, they have potential for development into clinical applications. 
Although bacteriocins are used in food preservation [29,37], no bacte-
riocin is currently commercially available as an antibiotic. 
This review aims to elucidate trends in research on the physico-
chemical and biophysical properties of bacteriocins and ascertain 
research directives for their subsequent clinical development. Strategies 
that have been suggested to date for the formulation of bacteriocins are 
discussed and essential parameters that are currently lacking for their 
development into medicines for antimicrobial-resistant infections are 
identified. 
2. Bacteriocins 
While the mechanism of antimicrobial activity and structur-
e–function relationship are critical to the performance of bacteriocins, 
they are beyond the scope of this review and are best described in a 
recent review by Cotter et al. [38]. Analysis of the bacteriocin database 
Bactibase showed that the number of Gram-negative bacteriocins that 
have been discovered is much lower than the number of Gram-positive 
bacteriocins with only 21 of the 230 bacteriocins documented being 
produced by Gram-negative bacteria. This proportion of Gram-negative 
versus Gram-positive bacteriocins is reflected in the bacteriocins that 
have generated significant academic research and published data, se-
lection shown in Table 1. The criteria for defining significant academic 
research and published data is based on those bacteriocins with a sig-
nificant amount of published data on, for example, their molecular 
weight, classification, antimicrobial activity, thermal and pH stability, 
solubility and/or enzymatic degradation. 
For bacteriocins that exhibit antimicrobial activity toward clinically 
relevant pathogens, a minimum inhibitory concentration (MIC) is 
essential to determine the required dosage concentration. Purified and 
formulated bacteriocins should have their MIC determined and 
Fig. 1. Modes of action typically employed by bacteriocins to inhibit competing bacteria, figure created using Biorender.com.  
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Table 1 
A collection of physicochemical data presented in the literature for a variety of documented bacteriocins, as available in December 2020.  
Bacteriocin* pI Solubility Stability Ref 
Susceptible to Not Susceptible Solution/pH Thermal 
(Gardimycin) 
Actagardine 
3.85 Insoluble in H2O, MeOH, 
DMSO. Soluble in 
acetonitrile:water (7:3), 
trifluoroethanol: water (9:1) 
N/a N/a 2.2–8.5, optimum ≤
6 
48 hr at room temp, 
decomposition at 260 ◦C 
[53,54 55] 
Acidocin 8912 9.87 N/a T, Pep, CT, ProK N/a N/a Up to 120 ◦C for 20 min [56] 
BacCH91 7.92 N/a N/a UL StpA/B/C 
(V8) PD, T, CT, 
Pep, ProK, ELT, 
CpsG 
Active pH 3–6 80 ◦C (up to 1 hr) [57] 
Bactofencin A 10.59 PBS, aq. T, ProK N/a N/a N/a [58] 
Bavaricin-A 9.13 N/a Pep, T, ProE, 
ProK,CT 
H2O2 Active pH 5–9.7 only 100 ◦C for 60 min [59] 
Boticin B 3.64 N/a N/a N/a N/a Heat stable [60] 
Bovicin HJ50 8.34 Hydrophobic, soluble in n- 
propanol 
T, SubT, ProK N/a N/a N/a [61] 
Carnocin UI49 6.41 Hydrophobic T N/a N/a <60 ◦C (pH 6.5) [62,63] 
Cinnamycin 
(Lanthiopeptin) 
8.05 EtOH,MeOH, DMF, DMSO. 
5 mg/ml in H2O, 10 mg/ml 
in DMSO 
N/a N/a Acidic conditions Decomposition at 245 ◦C [64] 
Curvacin-A 9.37 Low (aq.) ProK, T Pep, BSA, RNase Low stability Below 60 ◦C, 60–100 ◦C (30 
min) 
[65,66] 
Divergicin A 9.67 Very hydrophobic N/a N/a Rapidly degrades in 




8.04 N/a N/a N/a N/a Resistant to thermal 
degradation 
[68,69] 
Enterocin A 8.98 N/a T, Pep, Pap (85% 
degradation) 
N/a Active pH 2–8, 10 (12 
hr) 
100 ◦C at pH 2 and 4 [70] 
Enterocin E-760 8.91 N/a CT, ProK, Pap LZ, LP Stable pH 5–8.7 100 ◦C for 5 min [71] 
Enterocin NKR-5- 
3B (Ent53B) 
10.47 N/a T, CT N/a Human serum (24 




(particularly freeze thaw) 
[72] 
Enterocin P 8.22 N/a P N/a pH 2–11 (24 hr, 
25 ◦C) 
60 min (100 ◦C), 15 min 
(121 ◦C) 
[73] 
Enterolysin A 9.64 N/a ProK N/a N/a < 50 ◦C, no activity > 80 ◦C [74,75 76] 
Fulvocin-C 3.75 N/a N/a RNase, DNase, T, 
CT, Pro 
Active in Chloroform, 
EtOH, Acetone, 
Diethylether & Ethyl 
Acetate. 
80 ◦C for 30 min max. [77] 
Halocin-C8 4.4 N/a ProK T Can be desalted and 
subjected to organic 
solvents without 
losing activity 
100 ◦C for 1 hr [78] 
Hominicin 3.85 N/a ProK, T, CT, Pep, LP Active pH 2–10 Up to 121 ◦C for 15 mins [79] 
Lacticin 3147 Ltnα 5.44 N/a CT, T, ProA, ProK Pep N/a Heat stable, at a range of pH [40,80] 
Lacticin 3147 Ltnβ 8.51 N/a CT, T, ProA, ProK Pep 
Lacticin 481 (DR) 7.35 N/a Pro, Fic, ProK, CT T Opt. pH 6 stable pH 
2–10 
1 hr at 100 ◦C (pH 4.5, 7) [81 82] 
Lactocin-S 7.10 Hydrophobic – theoretical P T pH 4.5–9, not active 
> pH6. oxidative 
instability 
50% after 1 hr at 100 ◦C [83-87] 
Lactococcin 
MMFII 









8.77 N/a Pro, ProK LZ, Cat, CHCl3 pH 2–9, optimum 2–4 100 ◦C (30 min), active after 
121 ◦C (15 min) at pH 2–4 
only 
[90] 
Mersacidin 3.85 MeOH, CH3CH N/a N/a pH 5–7 at ambient 
temp. 
Ambient temperature [41] 
Mesentericin 
Y105 
8.77 N/a Pro, ProK, T, CT, 
Pep 
N/a Low pH only 100 ◦C for 120 min (pH 4.5) [91,92] 
Microcin J25 5.36 H2O, MeOH, up to 800 μg/ 
ml 
ProK, ElT, Pan CT, Pep, P (S. 
aureus V8), T 
pH 2–12 & 8 M urea 120 ◦C for 15 min [93-98] 





5.66 N/a N/a N/a pH 2–6, plasma half- 




5.66 N/a N/a N/a pH 2–6, plasma half- 
life 14 hr (IV) 
N/a [100,101] 
Nisin A 8.52 pH 2 highest CT, Nis, SubPep, 
Pan, Pep 
T < pH 6, optimum pH 
2 
Heat stable up to 121 ◦C, 15 
min 
[102-106] 
(continued on next page) 
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compared to the Clinical and Laboratory Standards Institute (CLSI) or 
the European Committee for Antimicrobial Susceptibility Testing 
(EUCAST) standard breakpoints. EUCAST specify determination of MIC 
using EUCAST disk diffusion methodology and subsequent inhibition 
zone diameters, whereby Mueller-Hinton (MH) agar or MH agar for 
fastidious organisms (MH-F) is typically utilised. Preparation and stor-
age of media, inoculum, turbidity standards, agar plate inoculation, disk 
application, incubation including conditions of incubation, examination 
of plates, measurement and interpretation of zones and quality control 
conditions are strictly defined (most recently updated in January 2021, 
V9.0) [39]. Most reported activity assays are performed using the well 
diffusion assay method with the cell-free supernatant or the purified 
bacteriocin resuspended in broth [40-44], indicative of their era of 
publication, as these modes of MIC determination were standard at the 
time, while newer standardised methods enable better comparative in-
hibition concentrations. Some re-suspend the bacteriocins in different 
buffers containing solubilising agents such as Tween 20/80, typically at 
concentrations of 0.1% [45-48]. While some bacteriocins show potent 
activity against a range of bacteria, including antimicrobial-resistant 
bacteria, there is only one bacteriocin mimic, brilacidin, in clinical tri-
als at present [49]. It has been well established that formulation stra-
tegies at the early stages of drug product development can be crucial for 
successful outcomes during preclinical and clinical phases of 
development, particularly for molecules with challenging physico-
chemical properties. In the next section, the physicochemical properties 
of bacteriocins and their potential influence on the progression of bac-
teriocins to clinical trials is critically assessed. 
3. Physicochemical properties of bacteriocins 
Bacteriocins, like any peptide or protein, can aggregate or unfold 
during formulation, in storage and in vivo [50]. This is known as physical 
instability as the chemical composition of the bacteriocin is unchanged, 
but its physical state changes. Chemical instability involves the pro-
duction of new chemical entities through the formation or breakage of 
covalent bonds within the bacteriocin [51]. This includes enzymatic 
degradation of proteins and bacteriocins, which can occur during pro-
duction or in vivo [52]. Bacteriocins can display low bioavailability or 
bioactivity depending on their permeability, stability and solubility in 
vivo. The physical and chemical stability data, available from the liter-
ature on bacteriocins is summarised in Table 1 and analysed in the 
subsequent discussions. The classification of these bacteriocins, their 
molecular weight, and bacteria against which the bacteriocins are active 
are available for reference (supplementary information). 
Table 1 (continued ) 
Bacteriocin* pI Solubility Stability Ref 
Susceptible to Not Susceptible Solution/pH Thermal 
Nisin Z 8.51 pH 3 (75 ◦C), higher 
solubility than nisin A at pH 
5 
CT, ProK, ActE T, Pap, Pep, LP, 
αA 
pH 3, stability 
reduced above and 
below 
Heat stable up to 121 ◦C, 15 
min 
[105,107,108] 
Nukacin ISK-1 8.53 N/a P, CT, Pep, Pan, 
Fic, Pap, ActE 
LZ, LP, RNase 
RNaseA, αA, T, 
ProK 





8.85  Pep, Pap, T, 
Protease IV/XIV/ 
XXIV/K, CT, Fic 
RNaseA, LZ, LP, Active pH 2–10 100 ◦C (60 min), 121 ◦C (15 
min) 
[110-112] 
Penisin (Elgicins) 7.8 N/a N/a ProK, T Stable at pH 2–12 Up to 100 ◦C, no more [113] 
Pep5 11.08 N/a T, CT, Pro Pep, αA, RNase, 
DNase, LZ, LS, 
CPD, PhLP 
Stable in aqueous, pH 
2–8 
80 ◦C for 1 hr, > 3 months at 
4 ◦C, lyophilisation 
[114] 
Plantaricin 432 N/a N/a CT, T, ProK, Pep, 
Pap 
N/a Active pH 1–10 Active at 80 ◦C, 50% activity 
at 100 ◦C for 60 min and 
25% activity after 
autoclaving (121 ◦C for 15 
min) 
[115] 
Plantaricin C19 9.87 N/a N/a N/a Active pH 5.5–7 only 7 ◦C to 37 ◦C (192 hr) [116 116] 
Plantaricin F 10.64 N/a Pep, Pro, T, ProK α-A, UV pH < 4.5 only, 
optimal pH 3.5 
100 ◦C for 30 min, 85 ◦C 1 
hr. Activity lost 90 min at 
35–100 ◦C 
[117,118] 
Plantaricin E 12.08 N/a N/a N/a N/a N/a  
Plantaricin W α 7.25 N/a N/a N/a Active from pH 2–6, 
loss above pH 7 
Tested from 4 ◦C to 100 ◦C, 
stable up to 121 ◦C for 15 
min 
[119,120] 
Plantaricin W β 10.63 




90 ◦C – 100 ◦C [121] 
Serracin-P 5.8 N/a ProE Pap, LP, T, RNase N/a Not heat-stable was 
destroyed at 50 ◦C (10 min). 
[122] 
Subpeptin JM4-B 7.30 N/a ProK, T ProE, Pep Active pH 2–8 20 ◦C to 120 ◦C for 30 min [123] 
Thuricin CD α 3.85 N/a N/a Pep, CT Active pH 2–9 Up to 85 ◦C, activity lost at 
100 ◦C 
[43,124] 
Thuricin CD β 3.85 N/a Pep, CT N/a 
Thuricin-17 3.55 N/a ProK, P Cat, αA pH 1.25–9 100 ◦C for 15 min [125,126] 
Thuricin-S 3.55 N/a ProK Pep, T, Pap Stable pH 3–10.5 100 ◦C, 10 min [44] 
Variacin 6.47 N/a ProE, ProK, Fic Cat Stable pH 2–10 Up to 115 ◦C [127] 
**.n/a indicates no data available. 
αA: α-Amylase, ActE: Actinase E, Cat: Catalase, CPD: Carboxy peptidase, CpsG: Catepsin G, CT: α-Chymotrypsin. 
DNase: Deoxy-ribonuclease, ElT: Elastase, Fic: Ficin, GA: Glucoamylase, LP: Lipase. 
LS: Lysostaphin, LY: Lyticase, LZ: Lysozyme, Nis: Nisinases, P: Protease, Pan: Pancreatin. 
Pap: Papain, PD: Peptidase, Pep: Pepsin, PhLP: Phospholipase, Pro: Pronase, ProA: Pronase A. 
ProE: Pronase E, ProK: Proteinase K, RNase: Ribonuclease, Sal9: Salvaricin 9, Stp: Staphopains. 
SubPep: Subtilo peptidase, SubT: Subtilisin, T: Trypsin, UL: Urealysin. 
* 19 bacteriocins presented in Table S1 were excluded due to a lack of published data. 
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3.1. Physical stability 
Physical instability in the form of aggregation and unfolding depends 
on the inherent properties of the peptide. It can result from changes in 
factors such as pH, ionic strength and temperature, causing a loss in 
solubility and subsequent loss in activity and biocompatibility. These 
factors are discussed below with respect to bacteriocins [128,129]. 
3.1.1. Solubility 
Low solubility is a major issue in the drug development process, 
reducing both in vitro and in vivo bioactivity [130]. Almost 70% of new 
drug candidates suffer from the problem of poor water solubility 
[131,132]. Antimicrobial therapeutics are no exception to this, with 
traditional small-molecule antibiotics exhibiting poor water solubility, 
such as tetracycline and ciprafloxacin [133]. Salt formation, if the drug 
is ionisable or formulation strategies such as the addition of solubilisers, 
nano-sizing, metastable crystalline/amorphous solid forms or the use of 
more soluble prodrugs can help to overcome these solubility challenges 
for small molecules. Careful selection of buffers and solubilising and 
stabilising additives are typically used to keep peptides and proteins 
stable in solution or with an additional lyophilisation step, in a recon-
stitutable solid form, before and after administration. Adequate solubi-
lity in physiological media is a prerequisite for good activity. 
While the majority of the reported literature on bacteriocins discuss 
and present their stability in terms of solution, thermal and chemical 
stability, very few report quantitative solution concentration data, 
Table 1. Quantitative solubility data is desired as it indicates the con-
centration of dissolved drug i.e. the amount of bacteriocin which would 
be in systemic distribution in vivo. Depending on the properties of the 
bacteriocin (e.g. isoelectric point, hydrophobicity/hydrophilicity, 
amino acid composition), certain pH values at different physiological 
locations in the body may cause the concentration of dissolved peptide 
to go below its MIC. This would lead to loss of activity and could cause 
an unwanted immune response in patients due to precipitation of 
aggregated peptide. Out of the bacteriocins listed in Table 1, only 11 
have reported solubility data. Out of this cluster of 11 bacteriocins, 
quantitative data was only found for nisin A/Z, microcin J25 and cin-
namycin [64,96,103-106]. Qualitative data alone was reported for the 
remaining 8 bacteriocins. Four studies reported conditions such as ‘low 
aqueous solubility’ for curvacin A, and ‘hydrophobic’ properties for 
lactocin-S, divergicin A and carnocin UI49 [63,66,67,85]. Four bacte-
riocins (actagardine, bovicin HJ50, bactofencin A and mersacidin) re-
ported certain organic solvents that solubilise the bacteriocin 
[41,55,58,61]. The grand average of hydropathy values (GRAVY) for 
each bacteriocin in Table 1 was analysed and it was found that 54.9% of 
these bacteriocins are hydrophobic (positive GRAVY index), and 45.1% 
hydrophilic (negative GRAVY index) (Fig. 2), an important consider-
ation in terms of their development into medicines. A list of the GRAVY 
index values is available (supplementary information) [36]. 
The lack of quantitative solubility data available, the reported low 
solubility of some bacteriocins in aqueous media and the bioinformatics 
analysis showing >50% of all bacteriocins in the Bactibase database as 
being hydrophobic, indicate that there could be challenges in keeping 
many bacteriocins in solution in the body. It is clear from Table 1 that pH 
will also play a role in the solubilisation of bacteriocins but the incor-
poration of solubilisers or complexing agents to improve aqueous solu-
bility could be inherently valuable at early stages of development. 
Alternative strategies to improve aqueous solubility could be the 
chemical modification of the bacteriocin but that could also inadver-
tently affect activity and/or specificity. The reported solubility of some 
bacteriocins in organic solvents could also enable a wide variety of 
formulation processes such as encapsulation in PLGA microspheres or 
solid lipid nanoparticles while retaining activity and high encapsulation 
efficiencies. Such strategies could be then used for long-acting therapies. 
3.1.2. Thermal and pH stability 
While bacteriocins often exhibit heat stability, Table 1, it’s important 
to note that it is not a universal property [134]. Bacteriocins that have 
been found to be thermostable generally exhibit efficacy at a wide pH 
range [135]. Out of the presented bacteriocins (Table 1), 23 were re-
ported to be stable up to 100 ◦C (time-dependent), while 8 other bac-
teriocins showed stability after treatment at 121 ◦C for 15 min. On the 
other hand, some bacteriocins such as plantaricin C19 or lactocin S do 
not report significant thermal stability. Certainly, it appears that the 
majority of bacteriocins are stable at or above body temperature, 37 ◦C, 
indicating that they will not degrade thermally in the body. Several of 
the bacteriocins are stable over particular pH ranges only, which may 
dictate what potential routes of administration should be used. For 
example, instability at low pH means that oral administration through 
the stomach will be challenging unless formulation strategies such as 
enteric coatings are used to protect the bacteriocin as it travels through 
the stomach. Instability at higher pH may compromise solubility, 
permeability and activity in the small intestine or indeed when the 
bacteriocin reaches systemic distribution. Low solubility at pH 7.4 may 
result in precipitation in the body which could induce an immunogenic 
response. Thus, solubilising strategies and careful dosage regimens 
would be necessary to ensure good bioavailability, low toxicity and good 
activity in vivo (see section 5). 
3.1.3. Aggregation 
Understanding how and under what conditions aggregation occurs is 
important in the development of bacteriocins into antibiotics to ensure 
the highest efficacy of the bacteriocin and the least toxicity in vivo. Bi-
ologics in their aggregated state are more prone to elicit immune re-
sponses than the parent monomer [136]. It has been reported that crude 
reutericin 6 self-aggregated, where aggregates were determined to be 
200 kDa in size [137]. Other bacteriocins that were reported to aggre-
gate include enterocin AS-37, which forms dimers and higher-order 
oligomers in aqueous solutions [138-140]. Enterocin P (EntP), another 
bacteriocin from Enterococci, also has a strong tendency to form ag-
gregates but the size and degree of oligomerisation of these EntP ag-
gregates, found through Western blotting with anti-EntP antibodies, was 
not presented. Gutierrez et al. suggested a considerable reduction in 
antimicrobial activity in the bacteriocins aggregated state [141]. 
Enterocin Q (EntQ) was also reported to aggregate when purified, pre-
sumably due to hydrophobic interactions. Interestingly, Cintas et al., 
reported these aggregates to be biologically active utilising an overlay 
assay [142]. Bhunia et al. showed that crude preparations of pediocin 
AcH tend to aggregate with other proteins and to precipitate during 
dialysis, but they showed that these aggregates had antimicrobial 
Fig. 2. Graph showing the percentage of all reported bacteriocins that are 
hydrophobic (54.9%) or hydrophilic (45.1%) based on their GRAVY index. Data 
sourced from Bactibase[36] 
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activity [111]. Other studies show aggregation of lacticin 481 at neutral 
or low pH’s [143], while lactocin S aggregates with lipid materials and 
in organic solvents (EtOH), which are required for stabilisation in its 
purified state [83,85]. Nisin was found to aggregate at high pHs (pH >
7/7.5) with dimers, trimers, tetramers and pentamers observed at pH 11 
[103]. Scherer et al. studied the aggregation of nisin in the presence of 
Lipid I, Lipid II and bactoprenol-diphosphate, the lipid responsible for 
the transport of peptidoglycan monomers across the cell membrane. 
They found that Lipid I/II induced aggregation, while nisin aggregates 
with bactoprenol-diphosphate were significantly smaller. They 
concluded that the membrane permeation capacity of nisin is deter-
mined by the size of bactoprenol containing aggregates in the membrane 
[144]. On the other hand, some bacteriocins, such as plantaricin C19 did 
not aggregate or associate with other substances under non-dissociating 
conditions [116]. Microcin J25 which is active at nanomolar concen-
trations was shown not to form aggregates up to 10 µM [145]. More 
experimental detail surrounding the conditions causing oligomerisation, 
the size of the aggregates, or the inhibitory activity of aggregates for 
bacteriocins would be valuable to enable rational selection of excipients, 
e.g. lipids, sugars, polymers, surfactants, etc. to reduce the risk of ag-
gregation, a common approach in the stabilisation of biologics in solu-
tion and upon administration [146]. Each bacteriocin may require a 
specific additive, depending on the mechanism by which it aggregates 
and its structure. Identification of the conditions under which aggre-
gation occurs would be crucial to identify when and what additive 
should be trialled to reduce this propensity. 
3.2. Chemical stability 
Different chemical instabilities such as proteolysis, oxidation, di- 
sulfide exchange, de-amidation and hydrolysis will affect bacteriocins, 
with resulting alterations in efficacy, pharmacokinetics and antigenicity. 
In the literature, a primary focus is given to proteolysis when discussing 
chemical degradation of bacteriocins with scant published data on other 
chemical degradation pathways. Proteolytic enzymes, or proteases, are 
the enzymes responsible for the break-down of proteins or peptides 
through proteolysis. Proteases are present in all organisms and have 
roles in digestion, apoptosis, signal transduction, haemostasis, repro-
duction and the immune system [147,148]. 
3.2.1. Enzyme susceptibility 
The human degradome contains 588 proteases, of which some are 
specific and some non-specific [149]. Specific proteases, such as the -
angiotensin-converting enzyme, target a unique peptide bond on one 
protein. Most proteases, however, are non-specific and target multiple 
substrates [148]. A-chymotrypsin, trypsin and pepsin are non-specific 
proteases found in the gastrointestinal tract (GI). A-chymotrypsin 
cleaves bacteriocins at the C-terminal side of the large hydrophobic 
residues leucine, phenylalanine, tyrosine, and tryptophan, amino acids 
that regularly exist in bacteriocins, thus increasing their susceptibility to 
proteolytic cleavage by this enzyme [34]. Trypsin cleaves at the C-ter-
minus of arginine and lysine. Pepsin works by cleaving peptide bonds 
between adjacent aromatic residues [150]. Pepsin is perhaps one of the 
most extensively studied proteases for several reasons from its ease of 
isolation from gastric fluids, to its high proteolytic activity. It is the only 
proteolytic enzyme in the human stomach, and is present at relatively 
high concentrations where it varies, depending on digestion, from 0.26 
to 0.58 mg/ml [131,151]. Other proteases exist in vivo and may also 
affect the stability of bacteriocins, such as those in the blood (like 
thrombin) as well as metalloproteases (such as collagenases). 
In vitro testing of the susceptibility of bacteriocins to enzymatic 
degradation in the literature utilises a variety of other enzymes, Table 1. 
Pronase is a trade name that describes a crude preparation of proteolytic 
enzymes. These enzymes are isolated from a broth culture of Strepto-
myces griseus, during the production of streptomycin [152]. Pronase E 
comprises multiple proteases and peptidases that hydrolyse 
glycoprotein peptide bonds from both termini [153]. Actinases hydro-
lyse peptides near proline residues [154]. Ficin is a sulfhydryl enzyme 
elaborated from the fig tree, containing a cysteine residue that shares 
many properties with papain. It hydrolysis peptide bonds, particularly 
those following an aromatic residue [155]. Another protease, proteinase 
K, is a serine protease from the mould Tritirachium album, and a member 
of the subtilisin family. It preferentially hydrolyses aromatic and hy-
drophobic amino acids [156]. Pancreatin comprises a multitude of 
digestive enzymes produced by the pancreas, including lipases, pro-
teases and amylases [157]. It appears, upon survey of the literature that 
bacteriocins are most susceptible to proteinase K (Fig. 3a), with most 
being tolerant to trypsin (Fig. 3b). It must be noted, however, that 
certain proteolytic enzymes would preferentially be utilised in in vitro 
studies for various reasons such as ease of availability and affordability, 
and as such may not fully represent the stability of bacteriocins in this 
regard. 
The only way to prevent enzymatic degradation in vivo is to essen-
tially inhibit the proteases (which could lead to other unwanted side 
effects) or to hide the bacteriocin from the proteases until it is near the 
target site of action. There is a wide range of delivery systems designed 
to protect their cargo from enzymatic degradation – PEGylation, 
encapsulation into a protective shell or matrix or chemical modification, 
some of which will be discussed in Section 5. Thus, if the bacteriocin 
under development is prone to protease degradation along the target 
route of administration, then such strategies should be employed. 
4. The cytotoxicity of bacteriocins 
The cytotoxicity of a compound is its toxicity towards eukaryotic 
cells i.e. its ability to cause cell death [158]. For compounds such as 
bacteriocins to be approved for use in humans, their cytotoxicity must be 
fully elucidated to ensure that, alongside their efficacy, the peptides are 
safe for use. Two common in vitro assays to determine the cytotoxicity of 
a substance is to measure its haemolytic activity and cell viability post- 
exposure [159]. There are several reports of toxicity data (in vitro and in 
vivo) in the literature on bacteriocins, Table 2. The high antimicrobial 
potency of bacteriocins may lead to toxic effects in vivo as AMPs also 
target eukaryotic cells, however the typically small size of most bacte-
riocins (<10 kDa), alongside their alteration of hydrophobic and hy-
drophilic patches provide some prokaryotic specificity, an advantage 
bacteriocins have over other AMPs [14]. 
Published bacteriocin toxicity studies include models for a range of 
routes of administration including oral, subcutaneous, intravenous, 
intranasal and intravaginal delivery, showing promise for their non- 
cytotoxic effects. All bacteriocins studied in vitro, except cinamycin 
and microcin J25, showed low toxicity at concentrations that were low, 
but above their active concentrations. Nisin A and pep5 showed toxicity 
to vaginal epithelial cells and lung fibroblasts, respectively, at high 
concentrations. These concentrations, however, are above that required 
for activity and therefore, should not be a cause for concern. Cinnamycin 
displayed toxicity against both cell lines tested, HeLa cells and human 
erythrocytes at low concentrations. Thus, cinnamycin may not be 
feasible for use as an antibiotic in humans. Microcin J25 showed toxicity 
towards rat heart mitochondria at low concentrations, but not to MDA- 
MB-435, MCF-7, RBC or IPEC-J2 cell lines. This highlights where 
microcin J25 should (GI and cutaneous) and should not (systemic) be 
administered in the body. Further studies are required for bacteriocins 
that display toxicity to certain cells, like cinnamycin and microcin J25, 
to elucidate alternative target sites or routes of administration. Colicins 
and microcins exhibit cytotoxic effects such as pore formation, pepti-
doglycan producer degradation, phosphatase activity, 16S rRNA tar-
geting activity and specific DNase and tRNAse activity [14]. As 
discussed previously (Section 2) several bacteriocins show low aqueous 
solubility or are active at particular pH values only. Care must be taken 
to ensure that the bacteriocin remains in solution and active during 
these in vitro and in vivo studies. If solubilising or stabilising strategies 
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are used to improve the solubility or stability of the bacteriocin, the 
cytotoxicity of the formulated bacteriocin must then be assessed as it 
may change the toxicity results due to higher solution concentrations 
and/or activities. The use of multi-hurdle strategies may help to curb 
potential cytotoxic effects by lowering concentrations of bacteriocin 
required, when administered with a traditional antibiotic, for synergistic 
antimicrobial effect [178]. 
5. Drug delivery strategies for bacteriocins 
It has been shown thus far, that many bacteriocins will need 
formulation strategies to improve their physicochemical properties for 
successful clinical development. Depending on these properties, appro-
priate routes of administration to increase their bioavailability, attain 
their therapeutic dose at the site of infection and increase their stability 
can be selected. Thus, protease degradation, aggregation and/or 
unfolding can be avoided during production and storage and in vivo 
[179]. 
5.1. Routes of administration and bioavailability 
All routes of administration, from parenteral to oral delivery, present 
challenges for the delivery of biologics like bacteriocins. The bioavail-
ability of a substance is largely dependent on its solubility and perme-
ability. Good water solubility allows a substance to dissolve in vivo and 
good permeability then allows the substance to diffuse through epithe-
lial layers to get to sites of action [132,180]. For example, for an orally 
administered molecule to reach systemic circulation, it must first pass 
through the epithelial lining, lamina propria and the vessel wall, while 
also surviving a range of pHs and degradation by enzymatic proteases 
and other metabolic processes [181]. A drug’s oral bioavailability is 
known to decrease when its molecular mass is >700 Da. The hydro-
phobicity of a drug also affects its bioavailability. The permeability of a 
molecule is higher the more lipophilic it is [50]. Although the large size 
(>700 Da) of most bacteriocins may decrease their bioavailability after 
oral administration, their hydrophobicity may increase their permeation 
leading to higher bioavailability than first expected. Intestinal perme-
ation can be modelled in vitro, in vivo and in situ. The Caco-2 cell system 
Fig. 3. (a) Susceptibility of the reported bacteriocins to proteases in Table 1 relative to their classification. Only bacteriocins susceptible to > 3 enzymes were 
included in this analysis and (b) Incidence of bacteriocins reported not susceptible to proteases in Table 1 relative to their classification. Only bacteriocins not 
susceptible to > 3 enzymes were included in this analysis. 
J. Flynn et al.                                                                                                                                                                                                                                    
European Journal of Pharmaceutics and Biopharmaceutics 165 (2021) 149–163
156
is the most characterised in vitro intestinal permeation model [182], 
while in situ models such as the intestinal perfusion model elucidate the 
mechanisms of adsorption and determine diffusion constants [183]. A 
study performed by Spadoni et al. confirmed that a molecule of 4 kDa 
(Fluorescent isothiocyanate (FITC)-low molecular weight dextran) could 
cross the gut-vascular barrier whereas one of 70 kDa (FITC-high mo-
lecular weight dextran) could not [184]. This contradicts the previous 
700 Da cut off discussed by Antosova et al. [50]. Kruszewska et al. 
suggested that the lantibiotic B, mersacidin, could be absorbed into the 
bloodstream from the nasal epithelium in mice, but indicated the need 
for additional studies [175]. A paper by Dreyer et al. presents the bac-
teriocins nisin A, plantaricin 423 and bacST4SA labelled with NHS 
fluorescein, where they showed the ability of those bacteriocins to cross 
epithelial and endothelial cells without changing the integrity of the 
monolayers or exhibiting toxic effects. They showed that 85% of plan-
taricin 423, 75% of nisin, and 82% of bacST4SA migrated across a Caco- 
2 cell monolayer within 3 h. The same studies on HUVEC cells showed 
migration levels across the cell monolayers of 93% plantaricin 423, 88% 
nisin, and 91% bacST4SA after 3 h. The hypothesised mode of transport 
was suggested to be paracellular based on the lack of toxicity observed, 
or alternatively, transcytosis. It also highlighted the need for increased 
permeability and cytotoxicity studies, apoptosis assays, haemolysis as-
says and more research into the mechanism involved in bacteriocins 
crossing epithelial cells [185]. A recent review by Dicks et al. best de-
scribes the permeability of bacteriocins across the gut blood barrier, 
concluding that bacteriocins may cross the gut blood barrier, although 
this may only be for a select few (studied by Dreyer), namely nisin A, 
plantaricin 423 and bacST4SA [186]. Thus some bacteriocins may be 
transported across the gut-blood barrier but the transport mechanisms 
are unclear and individual studies will be required for each bacteriocin, 
based on bacteriocin size, lipophilicity and potential carrier-mediated 
transport mechanisms. 
Even for local delivery to the gut, activity is not guaranteed – an 
L. lactis (DPC6520) bacteriocin producer survived the gastrointestinal 
tract but was not effective against L. monocytogenes in the colon [187], 
Table 3. For bacteriocins to act in the gastrointestinal tract, they must be 
protected from the proteolytic enzymes which may degrade them and 
from the varying pH of the GI [131]. The pH of the GI varies from pH 
1–2.5 in the stomach to pH 7.88 in the small intestine [105,188]. This 
leads to changes in the stability and solubility resulting in the loss of 
activity of bacteriocins as they move through the GI. As presented, 
however, low water solubility has been reported for several bacteriocins 
with no data available on aqueous solubility for many others, Table 1, so 
it is unclear if sufficient peptide will dissolve for many bacteriocins to 
allow for good activity [189]. For local delivery to the GI, the use of a 
matrix for bacteriocins to protect from pH or enzymatic degradation 
Table 2 
Toxicity studies reported for the bacteriocins outlined in Table 1.  
Bacteriocin Test Subject Outcome Ref 
In Vitro 
Cinnamycin  • HeLa  
• Human Erythrocytes  
• HeLa cells: toxicity was dependent on temperature,  
• The concentration of cinnamycin to induce 50% hemolysis of human erythrocytes in 4 min of incubation 
at 37 ◦C was 5 μM. 
[160 160] 
Enterocin AS48  • RAW264 cells  • Scarce toxicity to macrophages found. [140][161] 
Enterocin S37  • Caco-2 TC7  
• Caco-2  
• No significant effect on differentiated monolayer, no apoptotic affect up to 10 mg/L.  
• Cytotoxicity low for undifferentiated cells (8 hr, 10 μg/ml), increased toxicity after 24 hr (2–10 mg/L). 
[162] 
Lacticin 3147  • Equine blood cells  
• Distal colon model  
• Did not exhibit toxicity to equine blood cells.  
• A decrease in firmicutes and bacteriodetes, and an increase in proteobacter observed in the colon model – 
indicates a negative effect on gut health. 
[163,164] 
Microcin J25  • Rat heart mitochondria  
• MDA-MB-435  
• MCF-7  
• RBC  
• IPEC-J2  
• Rapid depolarisation of mitochondria membrane in rat heart, as low at 1 µM inhibits ATP production.  
• Low toxicity to MDA-MB0435, MCF-7 cells (100 μM, >80% viability).  
• Low haemolytic activity (RBC). Displays anti-apoptotic activity (isolated mitochondria).  
• No significant effect on IPEC-J2 cells – maintains the cell membrane integrity (up to 256 mg/L). 
[165-170] 
Nisin  • Caco-2, HT29  
• Vero  
• MRC-5  
• Vaginal cells  
• Sperm  
• Low toxicity to Caco-2 and HT29, indicates the potential for use in the GI.  
• Significant toxicity in vaginal epithelial cells only seen at high concentrations (95 μM).  
• Toxicity in Vero cells at 0.85–3.4 μM, no effect on mycoplasma/RBC (up to 1 μM). 
[171-173] 
Penisin  • RBC  
• HeLa  
• RWPE1  
• RAW  
• No haemolysis, even at high concentrations.  
• No toxicity to HeLa, RWPE1, RAW up to 40 μM (>80% viability). 
[113] 
Pep5  • Human lung fibroblast  • No haemolysis in sheep or human erythrocytes.  





• Albino CF mice (m/f)  • No signs of toxicity evident up to 250 mg/kg subcutaneously.  
• LD50 3,310 mg/kg subcutaneously. 
[53 174] 
Enterocin AS48  • BALB/c mice  • Administered at dietary levels up to 200 mg/kg for 90 days, no adverse effects. Very small degenerative 
changes in the liver. 
[140][161] 
Mersacidin  • Intranasal – Liver  • Intranasal administration did not cause mucosal lesions or morphological liver changes. [175] 
NAI-107  • CD-1 mice (female)  • Very low acute toxicity IV/SC at very high concentration (200 mg/kg). [101] 
Microcin J25  • Mice  
• Landace × Yorkshire ×
Duroc pigs  
• Orally administered to mice at concentrations of 4.55, 9.1 & 18.2 mg/kg. 9.1 mg/kg gave low 
inflammation.  
• Risk that high dosage mice had increased permeability and an imbalance of intestinal bacteria. 
[165-170] 
Nisin  • Holtzman rats  • No alteration to the oestrous cycle length or cell morphology, no histopathological lesions in the 
epithelium when administered intravaginally (14 days). Physiological function of the liver and kidneys 
were unaffected.  
• The fertility of treated rats was unaffected. 
[171] 
Penisin  • BALB/c mice  • Mice survived after 8 days of 80 mg/kg injections subcutaneously. [113] 
Plantaricin E & F  • ddY mice  
• Digestive tract health  
• No mortality even at high concentrations (LD > 5000 mg/kg (BW) per orally, 48 hr), with optimal doses 
being 250 and 500 mg/kgBW for E & F, respectively.  
• Only small amounts of mononuclear inflammatory cell infiltration.  
• Suggested benefits in digestive tract health. 
[101,176,177]  
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would improve their activity in the gut. Rectal administration via sup-
positories or enema preparations presents another option for local ac-
tivity in the GI, with high efficacy such as that seen by Rea, et al. [124], 
Table 3, although potential issues with patient compliance may pose a 
challenge to the development and marketing of these formulations. For 
systemic delivery through oral administration, formulation with pro-
tective matrices, solubilising additives and permeation enhancers may 
be required. 
Indeed, the main routes of administration for biologics are frequently 
intravenous (IV), subcutaneous (SC) and intramuscular (IM) [190,191], 
due to their challenging stability and permeability properties. IV infu-
sion is the most common form of parenteral administration for biologics, 
such as antibodies and recombinant protein therapies [192]. IV infusion 
bypasses many absorption barriers, efflux pumps and metabolic mech-
anisms, while also achieving therapeutic effective drug concentrations 
in minimal time [189,192]. There are drawbacks however, IV injections 
can be painful, expensive and invasive. Another issue is the solubility of 
a drug in an aqueous solution. This is important to prevent embolism or 
phlebitis as a result of precipitation [193]. SC administration also pos-
sesses drawbacks, such as limitations in volume available for adminis-
tration (typically < 1 ml to 2 ml), injection site degradation, local side 
effects brought on by retention of dose at the injection site, as well as 
increased inter-individual variability in dosages [194]. As such, quan-
titative solubility testing in simulated body fluids becomes an essential 
aspect of bacteriocin development. As recorded in Table 1, several 
bacteriocins exhibit low aqueous solubility and many have not reported 
whether or not they dissolve in an aqueous media and to what extent. 
Unlike IV administration, SC administration is more patient-friendly, 
can be administered by the patient and in comparison to IV infusion, 
reduces pain and discomfort significantly. IM administration is a more 
painful injection route due to the high density of muscle tissue and can 
lead to localised muscle tissue damage [192]. Many approved biologics, 
including those for managing chronic disease states or symptoms, are 
currently administered subcutaneously which would be a viable option 
for bacteriocins [190,195]. 
Of course, there are other modes of delivery for biologics, e.g. mar-
keted biological agents such as calcitonin, oxytocin and nafarelin are 
approved for intranasal administration. Irvine et al. best describes these 
routes of administration but a common theme arises whereby the short 
half-life of biologics in vivo increases the necessity for repeated admin-
istration or dosages, posing discomfort and poor patient compliance 
[190]. Local drug delivery (LDD) platforms can offer controlled and 
prolonged delivery of a drug alongside a range of advantages such as the 
reduced risk of systemic side effects. They can be administered directly 
to a site of infection, such as topical, periodontal, dermal or ocular 
administration [171]. LDD systems also offer advantages such as 
improved drug bioavailability at the target site and reduced dosage, thus 
providing improvements in patient compliance [196]. Studies have 
shown that when bacteriocins are administered subcutaneously, anti-
microbial effects have been detected both locally and systemically, for 
example, with lacticin 3147 and NAI-107 [101,197]. When NAI-107 was 
also delivered by IV infusion [101], similar results to its subcutaneous 
administration were observed. Penisin was also shown to be highly 
effective upon SC administration, with up to a 91% reduction in bac-
terial load of S. aureus in the thighs of mice [113], Table 3. Upon review 
of the literature, it would appear that local and SC/IV administration of 
bacteriocins show more suitability to treat bacterial infections outside 
the GI tract than oral administration [101,113,167,198]. 
5.2. Formulation approaches for Bacteriocins: State of the art 
While bacteriocins have been discussed in the literature for more 
than a century now, their development into medicines remains elusive. 
A myriad of different drug delivery strategies for active pharmaceutical 
ingredients, from nanoparticles (NP) of different materials to 
carbohydrate-based structures, tablets, gums and impregnated implants 
exist [200-202]. Studies of these strategies with bacteriocins are limited 
and focus on well known, and well-characterised bacteriocins, namely 
nisin and other LAB bacteriocins [203-210], S. salivarius bacteriocins 
[211-214], enterocins [215-217] and garvicin [178,218-220]. Ap-
proaches have involved studies of free bacteriocins in solution 
[167,175,197], conjugation to gold or silver nanoparticles [221-223], 
encapsulation in hydrogels [209,224], cyclodextrin complexes or lipid 
carriers [204,225-229] or adsorption to inorganic matrices [58,102], 
Figure 4. 
Improvements in stability and activity were generally reported from 
in vitro studies of these formulation approaches, Table 4, but only 
bacteriocin conjugated nanoparticles have been tested in vivo, Table 3 
[197]. Given that bacteriocins have demonstrated such instability to 
proteases, low aqueous solubility, a propensity to aggregation and pH- 
dependent activity, as discussed in Section 3, antimicrobial activities 
in vivo (Table 3) could be improved significantly by the use of the de-
livery strategies such as those summarised in Table 4 or derivatives 
thereof. 
5.3. Semisynthetic bacteriocins 
Although natural bacteriocins produced by bacteria have been the 
focus of this review, recent developments in synthetic/semi-synthetic 
bacteriocins are worthy of discussion. In November 2011, the semi- 
synthetic bacteriocin aminoheptylamido-deoxyactagardine B 
(NVB302) entered clinical trials through Novacta Biosystems Ltd. for the 
treatment of C. difficile infections [234,235]. The clean toxicological 
profile observed in pre-clinical studies was borne out in healthy 
Table 3 
Summary of reported in vivo studies on bacteriocins in infected animal models.  
Bacteriocin Formulation Route of 
Administration 
In vivo Outcome Ref 
Bacteriocin produced by 
L. acidophilus CH1 
Conjugated to gold NP’s Oral Sustained reduction in faecal spore shedding after treatment (94.26%). 
Reduction in intestinal spore load was highest with the conjugated bacteriocin 
in mice (89.7%). 
[199] 
L. lactis DPC6520 (Lacticin 
3147 producing strain) 
Cell suspension in PBS (109 CFU/ 
ml) 
Oral Survived the GI, not effective against L. monocytogenes in a mouse model or 
C. difficile in a human distal colon model. 
[187] 
Lacticin 3147 Suspension in PBS SC Prevented the systematic spread of S. aureus in a mouse model. [197] 
Mersacidin Suspension unspecified Intranasal Eliminated Methicillin-resistant S. aureus (MRSA) in blood, lungs, liver, 
kidney, spleen and nasal scrapings of an infected mouse rhinitis model. 
[175] 




Significant decrease of Salmonella newport in the infected spleen and liver of 
mice. 
[167] 
NAI-107 DMSO, β-hydroxypropyl 
cyclodextrin and glucose solution 
IV/SC Tested against murine septicaemia caused by S. aureus. Protected mice from 
septicaemia after IV and SC administration. 
[101] 
Penisin Suspension unspecified SC SC administration led to a 91% decrease in S. aureus MTCC96 load [113] 
Thuricin CD Enema preparations or 
suppositories in 10% EtOH 
Rectal 95% reduction in C.difficle in the colon of infected mice 1 h post rectal delivery 
of thuricin-CD 
[124]  
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volunteers. No serious adverse effects were reported up to a 1.5 g single 
dose or a 1 g daily dose (for 10 days). Rather, minor adverse effects were 
observed, which were independent of dosage. The phase I trials also 
showed that plasma levels of the lantibiotic were almost non-existent, 
conversely faecal levels of >1000x the MIC were obtained [234]. Pro-
gression of these trials doesn’t appear to be reported, however, an in-
ternational patent was published in 2014 [236]. 
Intrexon Corp. and Oragenics Inc. have also been involved in the 
publication of blueprints for further variants of mutacin 1140 such as the 
variant OG716, a promising progression in bacteriocin research 
[237,238]. Further developments have also included chemical synthesis 
of the bicyclic ring of mutacin 1140 by Oragenics Inc. and SynQuest 
Laboratories. This study presents the first report of a complete chemical 
synthesis, using orthogonally protected lanthionines, of the bicyclic C/D 
ring of mutacin 1140, although further characterisation is required 
[239]. While these recently published studies show incredible potential 
and progression in bacteriocin research for medical development, the 
lack of progression to clinical trials presents some uncertainty. 
5.4. Clinical development of bacteriocins 
The first clinical development of bacteriocins was reported in 1996, 
by AMBI/Astra. The NY based company planned to initiate clinical 
testing for Helicobacter pylori infection eradication using Ambicin 
(nisin). They planned to assess the in vivo safety and to progress to other 
tests combining nisin with compounds like Omeprazole, in a multi- 
hurdle approach, for the treatment of H. pylori infections in animals. 
Phase I clinical trials were reported to have gone ahead, however, phase 
II trials, scheduled to take place in 1997 were abandoned. Approval was 
also granted for the clinical phase I trials to treat C. difficile and 
vancomycin-resistant Enterococcus infections to proceed in 1997, how-
ever, no information was released. The product ‘Ambicin’ (a nisin based 
formulation used for bovine teat sanitisation prior to and post milking, 
for the prevention of mastitis [240]) was sold to Biosynexus in 2000. 
While under the hold of Biosynexus Inc., two National Institute of Health 
(N.I.H) grant applications in 2003 ($388,596 and $407,495) were 
approved for the development of a topical anthrax treatment using nisin 
[241]. However, no further outcome was reported. Ambicin was dis-
continued in Japan and the US in 2006. 
The bacteriocin Moli1901 (duramycin) was investigated in phase I 
trials for cystic fibrosis by AOP Orphan Pharmaceuticals AG. Phase II 
trials, completed in 2009, showed total cumulative aerosolised dose 
(0.9% saline administered via nebuliser canister) of 12.5 mg to be safe in 
human adult patients with CF, indicating a positive outcome. While the 
positive outcome of the phase II trials indicates the potential for further 
studies into its efficacy in CF patients, none appear to have been re-
ported [242-244]. 
6. Conclusion and future perspectives 
There exists a large panel of bacteriocins that exhibit a wide range of 
activities against clinically relevant bacteria. As noted by Cotter et al. in 
a Nature review in 2013, a severe lack of sufficient investment in bac-
teriocins has hindered their development into a new class of antibiotics 
[245]. In addition, from the data gathered in this review, comprehensive 
physicochemical characterisation of bacteriocins would enable the se-
lection of formulation strategies that could allow bacteriocins to prog-
ress more successfully through the stages of drug development. This is 
important data, imperative to the appropriate design of dosage forms 
and to maintain the efficacy of the bacteriocin during production, 
Table 4 
Formulation strategies explored for bacteriocins to date.  
Bacteriocin Formulation Route Outcome 
Bactofencin Mesoporous matrices (MSE and SBA-15) Oral Increased activity compared to free bactofencin against S. aureus [58]. 
Enterocin (produced by 
Enterococcus faecium 
FH99) 
Silver NP’s Food 
Preservation 
NP’s were found to be active against E. coli, L. monocytogenes and S. aureus at pg/ 
ml concentrations without displaying any toxicity to erythrocytes [216]. 
Bacteriocin produced by 
L. acidophilus CH1 
Conjugated to gold NP’s Oral Increased potency against microsporidia. The bacteriocin bound nanoparticles 
were also found to be non-toxic in mice (Table 3) [199]. 
Lacticin 3147 Ltnα & Ltnβ Solid lipid nanoparticles Oral Increased activity against C. difficile and indicated protection against 
α-chymotrypsin [230]. 
Lactocin 705, AL705, nisin Montmorillonite clay Food 
Preservation 
Increase in thermal stability for nisin up to 121 ◦C for 1 hr, with activity conserved 
for 10 days. The activity was conserved up to 18 months after storage at − 20 ◦C  
[231]. 
NAI-107 In DMSO, β-hydroxypropyl cyclodextrin 
and glucose solution 
IV/SC Protected mice from septicaemia caused by S. aureus when delivered via both 
routes (Table 3) [101]. 
Nisin Silver NP’s Food 
Preservation 
Increased antimicrobial activity against foodborne microbes compared to free 
nisin [222]. 
Nisin Hydrogel (Dextran and alginate) Local 
(injection) 
Controlled release of the lantibiotic nisin into simulated gastric fluid, along with 
improved antimicrobial activity against S. aureus 20,231 DSM (up to 10 days)  
[224]. 
Nisin Solid lipid nanoparticles (SLN’s) N/a Inhibition of L. monocytogenes and L. plantarum was observed over 15–20 days, 
whereas free nisin only inhibited for<3 days in solution [204]. 
Nisin Mesoporous matrices Oral Matrices loaded with nisin A were shown to remain active against S. aureus at pH 
6.5 [102]. 
Nisin Gum Arabic hydrogel microparticles N/a Enhanced the heat stability of the bacteriocin [206]. 
Nisin Hydrogel capsules(chitosan) Food 
Preservation 
Activity against B. subtilis was increased. Thermal and pH stability increased, max. 
activity observed at pH 5–6 [209]. 
Nisin Tablet(pectin and HPMC) Oral Dissolution up to 100% observed with controlled-release based on the 
concentration of HPMC [203]. 
Nisin & Lb. plantarum 
ATM11 bacteriocin 
Gold NP’s Food 
Preservation 
Combined antimicrobial activity against Micrococcus luteus, B. cereus, S. 
aureus and E. coli was increased [223]. 




Was shown to retain its activity against L. monocytogenes post encapsulation  
[225]. 
Pediocin AcH Lipid carriers (phospholipids) Food 
Preservation 
Maintained complete activity against L. monocytogenes, L. innocua and L. ivanovii 
for the first 13 days with a 50% decrease in activity thereafter [232]. 
Plantaricin 423 and ST4SA Electrospun hydrogelnanofibers (poly(D, L- 
lactide) and poly (ethylene oxide)) 
N/a Maintained 88% of their activity against E. faecium and were released from the 
fibres at a high concentration in the initial stages of the experiment [233]. 
Subtilosin Hydrogels (polyethylene glycol) Local 
(intravaginal) 
Sustained release of the bacteriocin, providing up to an 8 log reduction in 
G. vaginalis [198].  
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storage and after administration. Bacteriocins were found to be gener-
ally heat-stable but this is not a universal characteristic. Enzymatic 
stability varies greatly between bacteriocins but almost all bacteriocins 
have been reported to be susceptible to at least one protease tested. 
Quantitative solubility data in aqueous (and organic) solvents as well as 
permeability data would enable the development of better formulation 
strategies. Indeed, it would appear that local delivery may prove pref-
erential in the administration of bacteriocins as therapeutics – impor-
tantly though, this should not rule out further development for systemic 
applications, focusing on formulation/delivery strategies to improve 
solubility, stability and permeability to achieve optimal systemic dosage 
requirements. The generally positive cytotoxicity profile of bacteriocins 
and the favourable properties of semi-synthetic/synthetic bacteriocins 
lends promise to the development of clinical bacteriocin therapies. 
Unfortunately, at this stage, conclusions are difficult to draw in terms of 
whether future investment will be made into these antimicrobials for 
their development into next generation antibiotics, and their use in the 
mitigation of antimicrobial-resistant infections. 
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